Search Results

I-Mab today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer.

I-Mab, a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

I-Mab announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer.

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 30, 2024.

I-Mab announced that Gerald Falchook, MD, and the team at I-Mab’s partner for ragistomig, ABL Bio, will present a poster related to Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL.

I-Mab (the “Company”) (NASDAQ: IMAB) today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.